

Zynex Announces Filing of Patent for Sepsis Monitor

ENGLEWOOD, Colo., Jan. 14, 2021 /PRNewswire/ -- [Zynex, Inc.](#) (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today reported it has filed for a provisional patent for a noninvasive sepsis monitor.

Thomas Sandgaard, CEO of Zynex said: "Sepsis is one of the biggest problems in hospitals today. In the U.S. alone, over 1.7 million adults will develop sepsis annually with nearly 270,000 deaths as a result. Conventional patient monitors give insufficient advance warning of deteriorating patient health or the onset of potentially serious physiological conditions resulting from sepsis. A sepsis monitor that noninvasively measures patient condition and provides caregivers with an advanced warning or prediction of the onset of sepsis would be beneficial. A sepsis monitor may also be configured to provide or facilitate automatic intervention or treatment of sepsis and conditions resulting from sepsis. This sepsis monitor is capable of detecting potential sepsis in patients earlier than traditional methods, which has the potential to save lives. I believe the sepsis monitor will be a great complement to our CM-1500 Blood Volume Monitor, non-invasive detection of fluid balance in hospital settings."

Sepsis is a life-threatening medical condition characterized by the body-wide inflammatory response or reaction that presents in response to infection. The inflammatory response triggered by the immune reaction can cause body-wide tissue damage, even to areas not local to the original infection. Bacterial infections are the most common cause of sepsis, but sepsis can also be caused by fungal, parasitic, or viral infections. As an ineffectively treated infection progresses, toxins from the infection may circulate in the blood stream, causing damage to other organs (such as the brain, heart, lungs, kidneys, liver, etc.) and tissues. As the damage progresses, septic shock and a fatal decline in blood pressure may occur; patients with additional medical conditions and risk factors have increased likelihood of death.

Sepsis treatment spans multiple days to weeks, often in an intensive care environment and is detected through blood cultures, blood-gas analysis, kidney and other organ functional tests, platelet and white blood cell counts, additional imaging, urine testing, cerebrospinal fluid tests, etc.

The signs and symptoms of sepsis often may be subtle. The low survival rate of patients with severe sepsis indicates that current sepsis identification strategies, tools, and methods may be lacking.

About Zynex, Inc.

Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex also has a blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: www.zynex.com.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore you should not rely on any of these forward looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ

from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2019 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K.

Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact: Zynex, Inc. (800) 495-6670

Investor Relations Contact:

Amato And Partners, LLC

Investor Relations Counsel

admin@amatoandpartners.com

SOURCE Zynex

<https://zynexmed.investorroom.com/2021-01-14-Zynex-Announces-Filing-of-Patent-for-Sepsis-Monitor>